JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 80 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $101,000 | -19.2% | 14,942 | +0.2% | 0.00% | – |
| Q4 2021 | $125,000 | +16.8% | 14,918 | +3.8% | 0.00% | – |
| Q3 2021 | $107,000 | +35.4% | 14,372 | +24.1% | 0.00% | – |
| Q2 2021 | $79,000 | -34.7% | 11,579 | -1.8% | 0.00% | – |
| Q1 2021 | $121,000 | +40.7% | 11,787 | -3.9% | 0.00% | – |
| Q4 2020 | $86,000 | -20.4% | 12,260 | -7.6% | 0.00% | – |
| Q3 2020 | $108,000 | -51.8% | 13,274 | -59.1% | 0.00% | – |
| Q2 2020 | $224,000 | +176.5% | 32,475 | +91.3% | 0.00% | – |
| Q1 2020 | $81,000 | -50.0% | 16,978 | -8.7% | 0.00% | – |
| Q4 2019 | $162,000 | +134.8% | 18,604 | -10.4% | 0.00% | – |
| Q3 2019 | $69,000 | -25.8% | 20,762 | +10.2% | 0.00% | – |
| Q2 2019 | $93,000 | -29.5% | 18,847 | -11.4% | 0.00% | – |
| Q1 2019 | $132,000 | +230.0% | 21,264 | +80.6% | 0.00% | – |
| Q4 2018 | $40,000 | -88.7% | 11,776 | -74.5% | 0.00% | – |
| Q2 2018 | $354,000 | – | 46,230 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 9,200,349 | $64,402,000 | 44.86% |
| TRV GP III, LLC | 3,048,780 | $21,342,000 | 1.83% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 406,665 | $2,847,000 | 1.65% |
| Sofinnova Investments, Inc. | 925,280 | $6,477,000 | 0.39% |
| Omega Fund Management, LLC | 334,965 | $2,345,000 | 0.35% |
| Yorktown Management & Research Co Inc | 49,200 | $344,000 | 0.31% |
| Woodline Partners LP | 940,902 | $6,586,000 | 0.18% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 51,000 | $357,000 | 0.09% |
| HORIZON FINANCIAL SERVICES, LLC | 12,005 | $84,000 | 0.08% |
| Gyon Technologies Capital Management, LP | 26,893 | $188,000 | 0.06% |